# Changes in the metabolome, lipidomein, and gut microbiota in Behçet’s disease

**Authors:** Chen Shang, Sujuan Ji, Wenting Hao, Xiangyu Wei, Jiani Yu, Jiayi Liu, Baoguo Zhang

PMC · DOI: 10.3389/fcell.2025.1530996 · Frontiers in Cell and Developmental Biology · 2025-03-28

## TL;DR

This study found that people with Behçet’s disease have distinct gut bacteria and lower levels of certain metabolites compared to healthy individuals.

## Contribution

The study reveals novel insights into gut microbiota and metabolite changes specific to Behçet’s disease.

## Key findings

- BD patients showed reduced clostridia and increased γ-proteobacteria and betaproteobacteria in gut flora.
- Several metabolites were significantly lower in BD patients, including L-phenylalanine and ascorbic acid.
- Strong associations were found between specific metabolites and microbial families like Prevotellaceae.

## Abstract

There is growing evidence that autoimmune illnesses are associated with the metabolome and microbiota. Because Behçet’s disease (BD) is not often diagnosed as a systemic disorder, the aim of this research was to investigate changes in gut flora and metabolites in BD patients.

We used 16S rRNA gut microbiota gene sequencing and UPLC-QTOF-MS analysis to gather stool and serum samples from 12 age-matched healthy controls and 17 BD patients. The correlation between changes in gut microbiota and metabolites was then further analyzed.

In contrast to healthy controls, our investigation revealed significant changes in the makeup of gut flora in BD patients. In particular, we observed that in the BD group, there was a large drop in clostridia but a noticeable rise in γ-proteobacteria and betaproteobacteria. The serum metabolomics profiles of BD patients and healthy controls may be reliably differentiated using unsupervised principal component analysis (PCA). Several metabolites, including L-phenylalaine, tricarballylic acid, beta-leucine, ketoleucine, ascorbic acid, l-glutamic acid, l-malic acid, d-glucopyranuronic acid, and methyl acetoacetate, were found to have differential expression between BD patients and healthy controls. All of these metabolites were significantly lower in the BD group. Furthermore, we discovered strong associations between the detected metabolites such as tricarballylic acid, L-malic acid, D-glucopyranuronic acid with certain microbial families, such Prevotellaceae and Alcaligenaceae.

Patients with BD were found to have significant changes in the makeup of their gut flora and metabolites.

## Linked entities

- **Chemicals:** tricarballylic acid (PubChem CID 14925), beta-leucine (PubChem CID 193411), ketoleucine (PubChem CID 70), ascorbic acid (PubChem CID 9888239), l-glutamic acid (PubChem CID 23327), l-malic acid (PubChem CID 92824), d-glucopyranuronic acid (PubChem CID 94715), methyl acetoacetate (PubChem CID 7757)
- **Diseases:** Behçet’s disease (MONDO:0007191)

## Full-text entities

- **Diseases:** autoimmune illnesses (MESH:D001327), BD (MESH:D001528), systemic disorder (MESH:D009422)
- **Species:** Homo sapiens (human, species) [taxon 9606], Clostridia (class) [taxon 186801]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC11997388/full.md

## Figures

5 figures with captions in the complete paper: https://tomesphere.com/paper/PMC11997388/full.md

## References

70 references — full list in the complete paper: https://tomesphere.com/paper/PMC11997388/full.md

---
Source: https://tomesphere.com/paper/PMC11997388